Category Archives: James Martin

Julia Chronopoulos of the Martin Lab was awarded 2nd prize for her presentation at the Quebec Respiratory Health Research Days 2020 2020

Quebec Respiratory Health Research Day

Congratulations to Julia Chronopoulos of the Martin Lab in the Meakins-Christie Laboratories! Julia was awarded 2nd prize for her presentation Immunity to Influenza A Virus Infection during Pregnancy. The presentation was given during the first virtual edition of the Quebec Respiratory Health Research Days, held from November 9-11, 2020.

Congratulations as well goes to Julien Karim Malet of the Nguyen Lab for his active participation during this event.

RI-MUHC clinical trial COVID-19: clinical trial of ciclesonide to possibly prevent mild cases of COVID-19 from worsening

Ciclesonide Clinical Trial for COVID-19

Led by Dr. Nicole Ezer, a team of RI-MUHC researchers have initiated a clinical trial of ciclesonide to possibly prevent mild cases of COVID-19 from worsening.

Ciclesonide is an inhaled and nasal steroid drug currently used for asthma and nasal rhinitis. Laboratory studies have already shown that treatment with ciclesonide can decrease viral replication of SARS-Cov2, the virus responsible for the disease. This placebo-controlled randomized trial will confirm if the administration of inhaled and nasal ciclesonide can reduce the severity of respiratory symptoms among mild cases of COVID-19 and potentially avoid the need for hospitalization and oxygen.

Diagnosed with COVID? Contain COVID at the source. Protect your lungs! Register for a clinical trial of inhaled ciclesonide:

To learn more about the study:
please visit contain-covid19.com or email Info@contain-covid19.com

“We know the COVID-19 virus starts by multiplying in the nose and progresses downwards to the lower parts of the airways and lungs. We hope that targeting the site of viral replication with inhaled and nasal ciclesonide will reduce early viral replication and decrease severity of COVID-19 illness,”

– Nicole Ezer

Team Members

  • Nicole Ezer, Respirologist, MD, MPH
  • James Martin, Respirologist, MD, Dsc
  • Todd Lee, Infectious Diseases, MD Msc
  • Emily Macdonald, Internal Medicine, MD, Msc
  • Susan Bartlett, Clinical Psychologist, Senior Scientist
  • Andrea Benedetti, Epidemiology and Biostatistics PHD
  • Annie-Claude Jalbert, MD
  • Rola Hamed, MsC
  • Ankita Ghatak, MSc Candidate
  • Ben Smith, Respirologist, MD, Msc

Read more

Dr. James Martin, recipient of the 2020 ATS Assembly on Respiratory Structure & Function Joseph R. Rodarte Award.

James Martin Receives ATS Award

Dr. James Martin is this year’s recipient of the ATS Assembly on Respiratory Structure & Function Joseph R. Rodarte Award. Dr. Martin was nominated for this award by Dr. Basil Petrof, Director of the Meakins-Christie Laboratories.

This award is given in recognition of outstanding scientific achievement as a tribute to the outstanding attributes of the late Joseph R. Rodarte, who was an international leader in the fields of respiratory physiology and pulmonary medicine.

The award was presented at the RSF Assembly Virtual Membership Meeting held on Wednesday, June 24, 2020. Congratulations Dr. Martin!

‘Contain COVID-19’ – in its earliest phases

Dr. Nicole Ezer, Dr. James Martin, Dr. Andrea Benedetti and Dr. Ben Smith, all members of the RI-MUHC’s RESP Program, have recently announced their new COVID-19 study. This study is designed to test the efficacy of ciclesonide, a steroid currently on the market, to inhibit the spread of the COVID virus in its early stages. This new trial builds on the knowledge gained from a recent study using dexamethasone on advanced cases of COVID-19.

This new study, called Contain COVID-19, which will soon be in the recruiting stage, is aimed at decreasing the severity of shortness of breath among patients who have not yet been hospitalized. Dr. Ezer states in her recent interview with Mathieu Perreault of La Presse:

« Nous espérons que ça va diminuer la gêne respiratoire et éviter l’hospitalisation en stoppant la réplication virale et en diminuant la progression de l’inflammation dans les voies respiratoires inférieures. »

Eligible participants of the study will receive the medication (or placebo) in inhaler and nasal spray form at their residence, to be used for a period of 14 days. Ciclesonide was approved by Health Canada in 2008, and side effects are fairly uncommon, mild and cease when the medication is stopped.

Read more here:

Detailed information on the clinical trial as well as registration information, can be found:

https://www.contain-covid19.com/